Phi29 Motor Nanopore for Single Molecule Sensing: Breast Nipple Aspirate Fluid
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 2
- 试验地点
- 2
- 主要终点
- Biomarkers expression levels
研究概览
简要总结
This trial studies nipple aspirate fluid in detecting breast cancer. Nipple aspirate fluid may better detect breast cancer earlier than current methods used for screening such as mammograms and breast examinations.
详细描述
PRIMARY OBJECTIVES:
I. To obtain nipple aspirate fluid (NAF) samples from non-lactating women subjects at least 40-years-old.
II. To analyze the samples using a novel protein nanopore-based detection platform to evaluate the efficacy of the platform for breast cancer diagnosis through detection of biomarkers.
OUTLINE:
Participants and healthy volunteers undergo collection of nipple aspirate fluid from both breasts.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 40 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •BREAST CANCER: Must be > 1 year from pregnancy, lactation.
- •BREAST CANCER: Must be currently diagnosed with known breast cancer in breast.
- •BREAST CANCER: Must not be currently diagnosed with cancers other than breast cancer.
- •BREAST CANCER: Must not have been gone through surgery, radiotherapy or chemotherapy within 30 days of enrollment.
- •HEALTHY SUBJECTS: No history of breast cancer and must not be currently diagnosed with any other cancer.
- •HEALTHY SUBJECTS: Must be > 1 year from pregnancy, lactation.
- •HEALTHY SUBJECTS: Must be willing to have a clinical breast exam and/or mammogram performed or reviewed by an Ohio State University (OSU) radiologist at the James Cancer Hospital within the past 90 days prior to their NAF procedure. The clinical breast exam result and/or mammograms must be read as not suspicious for breast cancer.
- •HEALTHY SUBJECTS: Must be willing to keep the clinic informed of their breast health status for 1 year.
排除标准
- •Subjects who are currently pregnant, lactating, or within a year of pregnancy/lactation. Pregnancy testing will not be required of any patients over 60 years of age, or any patient who has undergone bilateral oophorectomy.
- •Subjects who currently are diagnosed with cancers other than breast cancer.
- •Subjects who cannot give an informed consent.
- •Male gender of any age.
结局指标
主要结局
Biomarkers expression levels
时间窗: Up to 1 year
Nipple aspiration fluid samples will be compared between breast cancer participants and healthy participants. will perform the logistic regression model for each biomarker that shows any difference between the breast cancer patients and healthy individuals. Then we will include multiple biomarkers in one model while controlling for confounders.
次要结局
未报告次要终点
研究者
William Carson
Principal Investigator
Ohio State University Comprehensive Cancer Center